Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 11, 2015, Pages 1202-1207

  Kappos, Ludwig ^a   Kuhle, Jens ^a   Multanen, Juha ^b   Kremenchutzky, Marcelo ^c   Di Cantogno, Elisabetta Verdun ^d   Cornelisse, Peter ^d   Lehr, Lorenz ^d   Casset Semanaz, Florence ^e   Issard, Delphine ^f   Uitdehaag, Bernard M J ^g  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Finnish MS Society   (Finland)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d MERCK SERONO S A   (Switzerland)

^e EMD SERONO INC   (United States)

^f Cytel Inc   (Switzerland)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; PLACEBO;

ADULT; ADVERSE DRUG REACTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; AGED; DISABILITY; DOSE RESPONSE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT SAFETY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON BETA-1A; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT SAFETY; PROGNOSIS; TREATMENT OUTCOME;

EID: 84947018862     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-310024     Document Type: Article

References (11)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-52.
2. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914-29.
3. Koch M, Kingwell E, Rieckmann P, et al. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81:1039-43.
4. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
5. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36.
6. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53.
7. Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord 2011;4:3-14.
8. Traboulsee A, Uitdehaag BMJ, Kappos L, et al. Clinical and magnetic resonance imaging predictors of long-term outcomes in patients with relapsing-remitting multiple sclerosis: additional analyses. Neurology 2011;76(Suppl 4):A389.
9. Bermel RA, Weinstock-Guttman B, Bourdette D, et al. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler 2010;16:588-96.
10. Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010;81:907-12.
11. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16:342-50.